The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer.

摘要: Despite the introduction of newer chemotherapeutic agents such as irinotecan, capecitabine and oxaliplatin, patients with metastatic colorectal cancer (mCRC) still have a poor prognosis. More effective better-tolerated treatment strategies are needed to improve patient outcomes, particularly in subsequent lines following chemotherapy failure. The favourable efficacy acceptable safety profiles anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) led approval panitumumab cetuximab monotherapy for EGFR-expressing mCRC whose tumours express non-mutated (wildtype) KRAS, after failure standard chemotherapy. Cetuximab is also approved combination this population. In phase III studies, demonstrated significant improvements progression-free survival when administered best supportive care (BSC) vs. BSC alone chemotherapy-refractory patients. A planned retrospective analysis trial was first large-scale clinical demonstration that confined expressing wild-type KRAS. It now recognised anti-EGFR mAb therapy should only be used While generally well tolerated, associated skin toxicity, severity rash has been proposed an early marker response treatment. BRAF, PTEN, PI3K emerging future potential predictive markers response; however, further studies warranted define role these biomarkers.